Home > Search Results: Adverse drug event
  Search Tips
Advanced Search
Search collections:
Sort by: Display results: Output format:
Results overview: Found 3 records in 0.02 seconds.
Articles, 3 records found
Articles 3 records found  
1.
11 p, 265.1 KB Safinamide in clinical practice : A Spanish multicenter cohort study / Martí-Andrés, Gloria (Clínica Universidad de Navarra) ; Jiménez-Bolaños, Rayco (Hospital Universitario Insular de Gran Canaria) ; Arbelo, José Matías (Hospital Universitario Insular de Gran Canaria) ; Pagonabarraga Mora, Javier (Institut d'Investigació Biomèdica Sant Pau) ; Duran-Herrera, Carmen (Hospital Universitario de Badajoz) ; Valenti-Azcarate, Rafael (Clínica Universidad de Navarra) ; Luquin, Maria-Rosario (Clínica Universidad de Navarra) ; Universitat Autònoma de Barcelona
Safinamide is an approved drug for the treatment of motor fluctuations of Parkinson's Disease (PD) patients with a potential benefit on non-motor symptoms (NMS). A retrospective multicenter cohort study was conducted, in which the clinical effect of safinamide on both motor and NMS was assessed by the Clinical Global Impression of Change scale. [...]
2019 - 10.3390/brainsci9100272
Brain sciences, Vol. 9 Núm. 10 (october 2019) , p. 272  
Detailed record - Creative Commons
2.
8 p, 500.8 KB Relative bioavailability of three formulations of galunisertib administered as monotherapy in patients with advanced or metastatic cancer / Gueorguieva, Ivelina (Eli Lilly and Company (United Kingdom)) ; Cleverly, Ann (Eli Lilly and Company (United Kingdom)) ; Desaiah, Durisala (Eli Lilly and Company (USA)) ; Azaro, Analía (Hospital Universitari Vall d'Hebron) ; Seoane Suárez, Joan (Vall d'Hebron Institut d'Oncologia) ; Braña, Irene (Hospital Universitari Vall d'Hebron) ; Sicart, Elisabet (Hospital Universitari Vall d'Hebron) ; Miles, Colin (Eli Lilly and Company (United Kingdom)) ; Lahn, Michael M.. (Eli Lilly and Company (USA)) ; Mitchell, Malcolm I (Eli Lilly and Company (USA)) ; Rodón Ahnert, Jordi (Vall d'Hebron Institut d'Oncologia) ; Universitat Autònoma de Barcelona
Galunisertib (LY2157299 monohydrate), an inhibitor of the transforming growth factor β (TGFβ) pathway, is currently under investigation in several clinical trials involving multiple tumor types. The primary objective of this study was to assess relative bioavailability of two new galunisertib formulations developed using the roller compaction (RC) dry-milled (RCD) and RC slurry-milled (RCS) processes, compared with the existing formulation developed using the high-sheer wet granulation (HSWG) process. [...]
2016 - 10.7573/dic.212303
Drugs in Context, Vol. 5 (December 2016) , art. 201303  
Detailed record - Creative Commons
3.
14 p, 606.8 KB Cafeína: un nutriente, un fármaco, o una droga de abuso / Pardo Lozano, Ricardo (Institut Hospital del Mar d'Investigacions Mèdiques) ; Álvarez García, Yolanda ; Barral Tafalla, Diego ; Farre, Magi (Institut Hospital del Mar d'Investigacions Mèdiques)
El café, el té, el chocolate y los refrescos de cola son las principales fuentes de cafeína, que es consumida en casi todas las edades y estratos socioeconómicos. La cafeína es un antagonista competitivo de los receptores adenosínicos del SNC. [...]
Coffee, tea, chocolate and caffeinated drinks are the main sources of caffeine, which is consumed in almost all ages and socioeconomic levels. Caffeine acts as a non-selective adenosine receptor antagonist in the central nervous system. [...]
2007
Adicciones, Vol. 19, Núm. 3 (2007) , p. 225-238  
Detailed record -

Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.
UAB Digital Repository of Documents :: Search :: Submit :: Personalize :: Help
Powered by Invenio v1.1.6
Maintained by ddd.bib@uab.cat  :: Metadata license:
Working with